- Home
- REPL vs NVRI Comparison
REPL vs NVRI Comparison
Compare REPL & NVRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- NVRI
- Stock Information
- Founded
- REPL 2015
- NVRI 1853
- Country
- REPL United States
- NVRI United States
- Employees
- REPL 331
- NVRI N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- NVRI Diversified Commercial Services
- Sector
- REPL Health Care
- NVRI Miscellaneous
- Exchange
- REPL Nasdaq
- NVRI Nasdaq
- Market Cap
- REPL 1.1B
- NVRI 750.9M
- IPO Year
- REPL 2018
- NVRI N/A
- Fundamental
- Price
- REPL $13.98
- NVRI $7.25
- Analyst Decision
- REPL Strong Buy
- NVRI Hold
- Analyst Count
- REPL 6
- NVRI 1
- Target Price
- REPL $19.83
- NVRI $10.00
- AVG Volume (30 Days)
- REPL 610.9K
- NVRI 617.9K
- Earning Date
- REPL 02-12-2025
- NVRI 02-20-2025
- Dividend Yield
- REPL N/A
- NVRI N/A
- EPS Growth
- REPL N/A
- NVRI N/A
- EPS
- REPL N/A
- NVRI N/A
- Revenue
- REPL N/A
- NVRI $2,342,645,000.00
- Revenue This Year
- REPL N/A
- NVRI $16.47
- Revenue Next Year
- REPL $1,065.54
- NVRI N/A
- P/E Ratio
- REPL N/A
- NVRI N/A
- Revenue Growth
- REPL N/A
- NVRI 13.21
- 52 Week Low
- REPL $4.92
- NVRI $6.57
- 52 Week High
- REPL $17.00
- NVRI $12.79
- Technical
- Relative Strength Index (RSI)
- REPL 55.54
- NVRI 25.67
- Support Level
- REPL $13.40
- NVRI $6.99
- Resistance Level
- REPL $14.59
- NVRI $9.30
- Average True Range (ATR)
- REPL 0.84
- NVRI 0.37
- MACD
- REPL -0.02
- NVRI -0.25
- Stochastic Oscillator
- REPL 66.52
- NVRI 10.20
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
About NVRI Enviri Corporation
Enviri Corp engages in providing a broad range of environmental services and related solutions. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company serves a diverse customer base by offering critical recycle and reuse solutions for their waste streams, enabling customers to address their complex environmental challenges.